论文部分内容阅读
对61例膀胱移行细胞癌患者的69价石蜡包埋肿瘤标本进行了流式细胞术(FCM)检测,结果显示肿瘤DNA倍体与肿瘤分级、分期和患者预后关系密切。DNA异倍体肿瘤出现率在病理1级、2级和3级分别为20.0％、64. 9％和72.7％,在1期、2期和3—4期分别为50.0％、68.8％和80.0％。二倍体和近二倍体肿瘤患者5年和10年无瘤生存率为81.5％和61.1％,而异倍体肿瘤患者分别为30.0％和0％。复发病人中,其原发肿瘤与复发肿瘤的DNA含量相关性差。肿瘤S期细胞比例增高表示肿瘤的恶性度高。FCM检测在肿瘤病理分级和分期的基础上能够提供更多预后信息。
Flow cytometry (FCM) was performed on 69 paraffin-embedded tumor specimens from 61 patients with transitional cell carcinoma of the bladder. The results showed that DNA ploidy was closely related to tumor grade, stage and prognosis. The incidence of DNA aneuploid tumors was 20.0%, 64.9% and 72.7% in pathological grade 1, grade 2 and grade 3, respectively, 50.0%, 68.8% and 80.0 %. The 5-year and 10-year tumor-free survival rates for diploid and near-diploid tumors were 81.5% and 61.1%, respectively, while aneuploid tumors were 30.0% and 0%, respectively. Relapsed patients, the primary tumor and recurrent tumor DNA content was poor. S phase tumor cells increased the proportion of high malignant tumor. FCM can provide more prognostic information based on tumor grade and staging.